*To the Editor*:

The rapid outbreak of coronavirus disease 2019 (COVID-19) has been a matter of international concern as the disease is spreading fast \[[@C1], [@C2]\]. Considering that the contagious disease has led to an enormous impact globally, there is an urgent need to identify the risk populations with poor prognosis. Ageing is associated with certain changes in pulmonary physiology, pathology and function, during the period of lung infection. Therefore, age-related differences in responsiveness and tolerance become obvious and lead to worse clinical outcomes in elderly individuals \[[@C3]\]. Previous studies have mentioned that older COVID-19 patients are at an increased risk of death \[[@C4]--[@C7]\]. However, the age-related clinical characteristics, disease courses and outcomes other than death in COVID-19 patients remain unclear.

In total, 221 COVID-19 patients who were diagnosed by the fever clinics of the designated hospitals were included in this study. They were administratively admitted to Shanghai Public Health Clinical Center (Shanghai, China) to receive medical care. The diagnosis was based on a positive response to viral nucleic acid detection, according to the updated version of the guidelines for the diagnosis and treatment of COVID-19 pneumonia issued by the National Health Commission of China \[[@C8]\]. Data on demographics, symptoms, disease severity and course, radiological and laboratory examination were analysed in our study. A unified observation end-point date was set in our study (7 March 2020). For all COVID-19 patients, the primary outcome of disease course and the secondary outcome of respiratory failure rate were compared in two age groups.

All 221 COVID-19 patients were divided into two groups, taking age 60 years as the threshold. The age distribution for all patients is shown in [figure 1a](#F1){ref-type="fig"}. 136 cases (61.5%) were aged \<60 years and the other cases were aged ≥60 years. In total, 176 patients (79.6%) had fever. Other common symptoms included cough (48.0%), sputum (25.8%), sore throat (8.6%) and diarrhoea (5.4%), among which only sore throat showed a significant difference between the two groups (11.8% *versus* 3.5%; p=0.034). Significant negative correlations between age of patients and lymphocyte counts (r= −0.432, p\<0.001) as well as albumin levels (r= −0.569, p\<0.001) were observed in our study ([figure 1b](#F1){ref-type="fig"} and c). Compared with the younger group, patients aged ≥60 years presented with higher levels of blood urea nitrogen (5.83 *versus* 4.42 mmol·L^−1^; p\<0.001), lactate dehydrogenase (272.8 *versus* 249.0 U·L^−1^; p=0.004) and inflammatory indicators ([figure 1d](#F1){ref-type="fig"}; all p\<0.01). In those aged ≥60 years, more lobes were involved (4.15 *versus* 3.34; p\<0.001) in bilateral lesions (89.4% *versus* 74.3%; p=0.006) ([figure 1e](#F1){ref-type="fig"}) and a higher proportion of patients showed bacterial co-infection (12.9% *versus* 4.4%; p=0.021). The severity of COVID-19 was milder in those aged \<60 years; this younger group showed lower proportions of severe and critical patients ([figure 1f](#F1){ref-type="fig"}). In turn, the utilisation of antibiotic therapy, intravenous corticosteroids and assisted ventilation was more common in those aged ≥60 years ([figure 1g](#F1){ref-type="fig"}). Longer disease courses and a higher proportion of cases with respiratory failure were observed in patients aged ≥60 years ([figure 1h](#F1){ref-type="fig"}). The median time of disease course was significantly longer in patients aged ≥60 years (24.0 *versus* 21.5 days; p=0.026) ([figure 1i](#F1){ref-type="fig"}). Interestingly, this difference was markedly significant in male patients (25.0 *versus* 21.0 days; p=0.036) but not in female patients ([figure 1j](#F1){ref-type="fig"} and k). A big difference in the median time of disease course was observed between the two age groups in cases with respiratory failure, although it showed no statistical significance (38.0 *versus* 30.0 days; p=0.100) ([figure 1l](#F1){ref-type="fig"}).

![Comparison of clinical features and outcomes of COVID-19 between two age groups, \<60 and ≥60 years. a) Age distribution for all 221 COVID-19 patients in Shanghai. Correlations were investigated between the age of patients and b) lymphocyte count (r= −0.432, p\<0.001), c) albumin level (r= −0.569, p\<0.001), d) C-reactive protein (CRP) level and erythrocyte sedimentation rate (ESR), and e) radiologically affected lobes. The difference in f) disease severity (classified as mild, common, severe or critical, according to the guidelines from the National Health Commission of China \[[@C8]\], but with no mild patients in our cohort), g) treatment, and h) disease course and rate of respiratory failure in the two age groups were also investigated. Cure rates of COVID-19 are shown for i) all 221 patients, j) males, k) females and l) those with respiratory failure. \*: p\<0.05; \*\*: p\<0.01; \*\*\*: p\<0.001.](ERJ-01112-2020.01){#F1}

This is the first study to systematically evaluate the impact of age on the clinical characteristics and important outcomes for COVID-19 patients, thus helping clinicians to establish risk stratification of COVID-19 patients as early as possible. Sporadic studies have mentioned that elderly people may tend to die after infection \[[@C5], [@C7], [@C9]\], calling on the public to pay more attention to protecting the elderly from the virus. In this study, we demonstrated that the clinical characteristics and outcomes of 221 COVID-19 patients were closely related to the different age groups. This study provides clear evidence of a relationship between disease severity and age, which other studies have not. Comprehensive analysis of these indicators will provide physicians worldwide with important information for disease perception, condition assessment and effective treatments for COVID-19.

The proportion of patients using antibiotics was higher in patients aged ≥60 years than in patients aged \<60 years, possibly due to the higher proportion of patients with bacterial co-infection in this group. Besides, older patients showed more serious illness, leading to higher frequency of adjuvant therapies including corticosteroids and assisted ventilation in this group of patients. Consistent with recent reports \[[@C10], [@C11]\], older patients presented significantly lower levels of lymphocytes than younger patients. Lymphocytes are generally elevated in response to common viral infections, but are abnormally decreased in severe acute respiratory syndrome (SARS) and COVID-19 \[[@C12]--[@C14]\]. Although the underlying mechanism is still unclear, the low level of lymphocytes could be a key indicator of disease severity in COVID-19. Furthermore, other serological indexes, such as albumin level, blood urea nitrogen, lactate dehydrogenase and inflammatory indicators, also showed a progressive trend with age. The phenomenon is obvious; however, we cannot identify whether these changed indicators result in or result from the differences in disease severity with age.

Although most patients had favourable prognosis in this study, some patients required longer periods of treatment, which might have turned out worse due to the high risk of hospital-acquired or iatrogenic infections. Age was one of the risk factors for disease severity and mortality in viral infection studies \[[@C5], [@C9]\], although the data about age in those studies are approximate. Our study found that COVID-19 patients aged ≥60 years had a higher rate of respiratory failure and needed more prolonged treatment than those aged \<60 years, demonstrating that elderly COVID-19 patients had much more severe disease and showed poorer response to treatments than the younger age group. The cure rate of patients aged ≥60 years (89.4%) was relatively lower than that of patients aged \<60 years (95.6%), especially in males and those with respiratory failure. A previous study indicated that there might be a sex predisposition to COVID-19, with men more prone to be affected, but gave no evidence of an association between the severity of COVID-19 and the male sex \[[@C15]\]. More attention needs to be paid to these older patients with respiratory failure, and aggressive early intervention should be made to improve their prognosis. With more cases being examined from different ethnic and genetic backgrounds, the findings related to age in this study may be confirmed by physicians worldwide.

In conclusion, the clinical features and prognosis of the disease vary among patients of different ages and a thorough assessment of age may help clinicians worldwide to establish risk stratification for all COVID-19 patients. Patients aged ≥60 years showed heavier clinical manifestations, greater severity and longer disease courses compared with those aged \<60 years. Closer monitoring and more medical interventions may be needed for the elderly.
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